Histamine 2‐Receptor Antagonists Tachyphylaxis: A Scoping Review
The Laryngoscope · 2026-06 · 136 (6) · 2412-2425
DOI: 10.1002/lary.70337 ↗Kurz gefasst
Scoping Review in der Zeitschrift The Laryngoscope, online erschienen am 29.12.2025. Verfasst von James H Clark und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Histamine H2 Antagonists, Gastroesophageal Reflux, Tachyphylaxis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
Objective
Histamine 2‐receptor antagonists (H2RAs) commonly treat gastroesophageal reflux disease (GERD). However, tachyphylaxis, defined as the rapid reduction of efficacy, is frequently reported and remains poorly understood. This investigation performed a scoping review on the decrease in H2RA efficacy with repeat dosing. Data Source Following PRISMA‐ScR guidelines, we systematically searched PubMed, Embase, Scopus, Web of Science, and the Cochrane Database through August 27, 2025. Review Method Two reviewers independently screened studies and extracted data on mechanisms, impact, and management strategies.
Results
While H2RAs effectively reduce gastric acid secretion, continuous dosing leads to tachyphylaxis of unclear etiology. Initial H2RA treatment increases the percentage of time intragastric pH is > 4, from 8% to 38%. Tachyphylaxis begins by the second dose, 2, with an 11.2% reduction in efficacy by day 3. By day 15, tachyphylaxis results in a 13.0%–27.5% (mean: 20.3%) decrease in efficacy, after which no further reduction in effectiveness occurs. In comparison, once‐daily proton pump inhibitors maintain a daily intragastric pH of 63% above 4, with no tachyphylaxis observed after 14 days.
Conclusion
Tachyphylaxis is a well‐documented, diminished treatment effect observed across the entire class of H2RAs. It typically begins by day 2 and plateaus quickly, resulting in up to a quarter decrease in absolute efficacy. The precise mechanisms underlying H2RA tachyphylaxis remain uncertain. H2RAs should not be prescribed as first‐line agents for the management of frequent GERD or routinely added in cases of incomplete response to PPIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Capital Digestive Care, Rockville, Maryland, USA.
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, California, USA.
- Department of Otolaryngology-Head and Neck Surgery, University of California, Davis, Sacramento, California, USA.
ORCID-Profile: James H Clark, Lee Akst, Peter C Belafsky
Zitieren
APA
Clark, J. H., Hussain, Z., Akst, L., Marks, S. L., & Belafsky, P. C. (2026). Histamine 2‐Receptor Antagonists Tachyphylaxis: A Scoping Review. The Laryngoscope, 136(6), 2412-2425. https://doi.org/10.1002/lary.70337
Vancouver
Clark JH, Hussain Z, Akst L, Marks SL, Belafsky PC. Histamine 2‐Receptor Antagonists Tachyphylaxis: A Scoping Review. The Laryngoscope. 2026;136(6):2412-2425. doi:10.1002/lary.70337
BibTeX
@article{Clark2026,
author = {Clark, James H and Hussain, Zilla and Akst, Lee and Marks, Stanley L and Belafsky, Peter C},
title = {Histamine 2‐Receptor Antagonists Tachyphylaxis: A Scoping Review},
journal = {The Laryngoscope},
year = {2026},
volume = {136},
number = {6},
pages = {2412--2425},
doi = {10.1002/lary.70337}
}
EUVIMED